Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2019

View Archived Issues

Amgen presents first-in-human data for AMG-595 in patients with recurrent glioblastoma

Saniona selects IK channel inhibitor SAN-903 as new preclinical candidate

Cell Pouch is well tolerated and shows signs of efficacy in type 1 diabetes patient

ACCORDANCE study of AP-CD/LD does not achieve statistical superiority on the primary endpoint

Achillion presents promising data from phase I MAD study of ACH-5228

First patient treated in phase I/II study of sapacitabine and venetoclax in AML or MDS

Patrys presents promising preclinical data for PAT-DX1 in models of highly aggressive GBM

Spectrum expands ZENITH20 phase II study of poziotinib

Sun BioPharma offers update on front-line pancreatic cancer study of SBP-101

WMJ-J-2 as a promising new preclinical candidate for the treatment of CRC

Discovery and preclinical identification of novel NOX1-selective inhibitor, 2APT-PD06

First-generation PI3KC2alpha inhibitors as promising antithrombotic agents

Metabolic disorder and neuroinflammation alleviated by novel CB1 receptor antagonist in AD models

Daewoong Pharmaceutical describes new BTK and/or JAK3 inhibitors

Shanghai Institute of Cell Therapy, Shanghai Cell Therapy Group patent EGFR-specific CAR-T cells

Innovent Biologics presents antibodies targeting LAG-3, PD-L1

Hepatitis B virus HBsAg and DNA inhibitors discovered at Roche

RIKEN and collaborators describe tankyrase and/or tubulin polymerization inhibitors

BK-40143: a novel small-molecule inhibitor of discoidin domain receptors

Parkinson's other balance problem

GLP-1/GIP dual antagonist mitigates pilocarpine-induced neurotoxicity in rats

New assays mean new insights into HIV reservoir

Arcutis reports promising topline phase IIb data on ARQ-151 for plaque psoriasis

Salarius enrolls first patient in phase I study of seclidemstat in advanced solid tumors

Dolutegravir recommended by WHO for first-line and second-line treatment for HIV

Acadia reports phase III topline results on pimavanserin as adjunctive treatment for schizophrenia

Japanese phase III study of Lonasen in adolescents with schizophrenia meets primary endpoint

VenatoRx announces collaboration to develop VNRX-5133 to treat drug-resistant infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...